SCHEMBL29699515

SCHEMBL29699515

Brc1ccc2cc(Nc3c[nH]nn3)ccc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
MAPT P10636 4/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
PABPC1 P11940 1/20 0.37
CYP2A6 P11509 1/20 0.37
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
ABL1 P00519 1/20 0.35
AGPAT2 O15120 2/20 0.34
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
GSK3A P49840 1/20 0.33
CDK9 P50750 1/20 0.33
CDK5 Q00535 1/20 0.33
TAOK1 Q7L7X3 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23457500 1.00 MEN1 (0.37) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL15831504 0.83 MAPT (0.43) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL29699617 0.83 SCN9A (0.38) MAPTRAB9ANPC1CYP2A6AGPAT2
SCHEMBL23457623 0.83 SCN9A (0.38) MAPTRAB9ANPC1CYP2A6AGPAT2
SCHEMBL8842380 0.82 ABCG2 (0.43) MAPTKDM4EABL1CYP3A4MAPK1
SCHEMBL29699470 0.73 POLA1 (0.47) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL4149136 0.70 MAPK10 (0.49) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL27855038 0.70 NOS1 (0.38) MEN1KMT2AMAPTCYP2A6ALDH1A1
SCHEMBL15831508 0.70 RAPGEF4 (0.45) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL828555 0.70 MEN1 (0.48) MEN1KMT2AMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT MEN1 2988/4885KMT2A 4011/4885MAPT 1215/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT MEN1 2927/4885KMT2A 3699/4885MAPT 1082/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT MEN1 2988/4885KMT2A 4011/4885MAPT 1215/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT MEN1 2988/4885KMT2A 4011/4885MAPT 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.